Nadir platelet and neutrophil counts during the course of PEG-IFN .ALPHA.-2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy

DOI Web Site Web Site 32 References
  • Karino Yoshiyasu
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Toyota Joji
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Arakawa Tomohiro
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Kuwata Yasuaki
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Akaike Jun
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Yamazaki Katsu
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Sato Takahiro
    Department of Gastroenterology, Sapporo Kosei General Hospital
  • Ohmura Takumi
    Department of Gastroenterology, Sapporo Kosei General Hospital

Bibliographic Information

Other Title
  • ＰＥＧ－ＩＦＮα－２ｂとリバビリン併用療法において血小板数および好中球数の最低値は投与１週目値から予測可能である－有効性の向上をめざして
  • PEG IFN アルファ 2b ト リバビリン ヘイヨウ リョウホウ ニ オイテ ケッショウバンスウ オヨビ コウチュウキュウスウ ノ サイテイチ ワ トウヨ 1シュウメチ カラ ヨソク カノウ デ アル ユウコウセイ ノ コウジョウ オ メザシテ
  • Nadir platelet and neutrophil counts during the course of PEG-IFN α-2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy

Search this article

Abstract

In the treatment of chronic infection with genotype 1 hepatitis C virus, good compliance to PEG-IFN treatment schedule is extremely important to achieve virological response. With the objective of assuring the administration of adequate doses, we examined whether the dose reduction according to the criteria in the package insert of PEG-IFN α-2b is really needed or not. In the past 10 years after approval in Japan , IFN α-2b has been administered, as a rule, without dose reduction. No significant difference is observed following the administration of 6 MIU of IFN α-2b and 1.5 μg/kg of PEG-IFN α-2b in the change in blood cell parameters. To assure safety when PEG-IFN α-2b is administered without dose reduction, the correlation between nadir values during the treatment period and the weekly or monthly measurement values was examined. The results indicated that it is possible to predict nadir values during the treatment period from measurement value after one week of treatment (Platelet: r'2=0.6011, P<0.0001, Neutrophil: r'2=0.6801, P<0.0001). No safety problems were observed if we did not strictly follow the dose reduction of PEG-IFN α-2b settled in the package insert. To achieve improvement in efficacy with PEG-IFN α-2b plus ribavirin combination treatment, early reduction of the dose of PEG-IFN α-2b should be avoided while conducting periodic monitoring of blood cell parameters.<br>

Journal

  • Kanzo

    Kanzo 49 (6), 239-247, 2008

    The Japan Society of Hepatology

References(32)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top